Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGSF8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGSF8 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IGSF8 Products |
| Gene Delivery | IGSF8 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based conformation assays. |
View IGSF8 Products |
| Benchmark Ab | Anti-IGSF8 (Sequence of PYX-106) Recombinant positive control. Sequence Verified. High Purity. |
View IGSF8 Products |
| Validator | IGSF8 siRNA Set For knockdown verification in target-positive tumor cells. |
View IGSF8 Products |
| Related Target A | CD81 Tetraspanin partner that physically associates with IGSF8 to regulate cell migration and immune signaling. |
View CD81 Products |
| Related Target B | LILRB1 Inhibitory receptor involved in immune evasion pathways overlapping with IGSF8-mediated suppression. |
View LILRB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified, and Endotoxin Controlled. |
| Subfamily counter-screening (avoiding off-target binding) | Homolog panel proteins strictly verified by mass spectrometry and biochemical profiling. |
| Lack of positive control benchmarks | Clinical Benchmark Antibodies (Biosimilars based on PYX-106 sequence) included in the catalog. |
| False positives in binding assays | Validated siRNA included for specificity checks and target knockdown verification. |
Live IGSF8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGSF8 therapeutics is intensifying, with major players shifting focus from traditional immune checkpoints to novel macrophage- and NK-cell-modulating targets. As first-generation therapies reach the clinic, the next wave of R&D is targeting IGSF8 as a major innate immune checkpoint that suppresses both T-cell and NK-cell activity in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Pyxis Oncology (PYX-106) | Advanced Solid Tumors (HNSCC, NSCLC, Thyroid Cancer) | Receptor blocking assays & Cyno cross-reactivity (Need Sequence-Verified ECD-Fc proteins) |
| Antibody-Drug Conjugate (ADC) | Preclinical programs | High-expressing epithelial tumors | Internalization assays (Need Lentivirus for Stable Cell Line development to preserve native conformation) |
| Combination Therapies | Immuno-oncology innovators | PD-1 resistant cold tumors | Synergistic screening panels (Need validated CD81 and LILRB1 proteins) |